--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ZBIO20260220P15
Pharmaceutical
Zenas BioPharma, Inc., was originally incorporated in Cayman on November 12, 2019 under the name Zenas BioPharma (Cayman) Limited. On August 2, 2023, the company was incorporated in Delaware and simultaneously changed its name from Zenas BioPharma (Cayman) Limited to Zenas BioPharma, Inc. They are a clinical-stage global biopharmaceutical company dedicated to developing and commercializing immune-based transformative therapies for patients in need. With the growing understanding of the pathogenesis of autoimmune diseases and the expansion of promising immunology-based pharmacological targets, they are building a biopharmaceutical company focused on immunology and inflammation (" I & I ").
